Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases
- PMID: 12140105
- DOI: 10.1016/s0303-8467(02)00054-9
Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases
Abstract
To compare the clinical features of patients with the Lambert-Eaton myasthenic syndrome (LEMS) associated with carcinoma, with patients having LEMS but no cancer, reports on LEMS patients were analyzed systematically. Cancer was detected (CD group) in 62% of the 227 included cases. This CD group showed a male predominance (70%). No sex difference was found in patients in whom no cancer was detected (NCD group). Median age at onset of LEMS in the CD group was higher than in the NCD group (58 and 49.5 years, P<0.01). Median interval between onset of symptoms and diagnosis of LEMS was longest in NCD cases (P<0.001). CD patients had additional immunological disorders less frequently than NCD cases (6 and 27%, P<0.001). Symptoms distinguishing the CD group from the NCD group were weight loss (P<0.001) and need for prolonged artificial ventilation after anaesthesia (P<0.05). This analysis shows significant differences between CD and NCD cases of LEMS. The male predominance and higher age at onset in patients with a tumor probably reflects the characteristics of patients with small cell lung cancer. The high frequency of additional immunological disorders in patients without malignancy, together with the younger age at onset suggests a similar etiology as other non-paraneoplastic autoimmune diseases.
Similar articles
-
Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.J Neurol. 2017 Sep;264(9):1854-1863. doi: 10.1007/s00415-017-8541-9. Epub 2017 Jun 12. J Neurol. 2017. PMID: 28608304 Review.
-
SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.Neurology. 2008 Mar 18;70(12):924-8. doi: 10.1212/01.wnl.0000281663.81079.24. Epub 2007 Nov 21. Neurology. 2008. PMID: 18032743
-
Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.Ann N Y Acad Sci. 2008;1132:129-34. doi: 10.1196/annals.1405.030. Ann N Y Acad Sci. 2008. PMID: 18567862
-
[Paraneoplastic Cerebellar Degeneration with Lambert-Eaton Myasthenic Syndrome: A Report of an Effectively Treated Case and Systematic Review of Japanese Cases].Brain Nerve. 2019 Feb;71(2):167-174. doi: 10.11477/mf.1416201237. Brain Nerve. 2019. PMID: 30718446 Japanese.
-
Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.Brain. 1997 Aug;120 ( Pt 8):1279-300. doi: 10.1093/brain/120.8.1279. Brain. 1997. PMID: 9278623
Cited by
-
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.Neurol Sci. 2014 Apr;35(4):515-20. doi: 10.1007/s10072-014-1637-4. Epub 2014 Jan 31. Neurol Sci. 2014. PMID: 24481713 Review.
-
3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.BMC Neurol. 2021 Sep 25;21(1):371. doi: 10.1186/s12883-021-02405-3. BMC Neurol. 2021. PMID: 34563155 Free PMC article.
-
Paraneoplastic Lambert-Eaton myasthenic syndrome: a diagnostic challenge.BMJ Case Rep. 2023 Jan 27;16(1):e250947. doi: 10.1136/bcr-2022-250947. BMJ Case Rep. 2023. PMID: 36707096 Free PMC article.
-
Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan.BMJ Neurol Open. 2022 Sep 5;4(2):e000291. doi: 10.1136/bmjno-2022-000291. eCollection 2022. BMJ Neurol Open. 2022. PMID: 36110924 Free PMC article.
-
Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer.Cureus. 2023 Jan 9;15(1):e33557. doi: 10.7759/cureus.33557. eCollection 2023 Jan. Cureus. 2023. PMID: 36779131 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources